Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated
Journal of Hepatology · 2023-05 · 78 (5) · 989-997
DOI: 10.1016/j.jhep.2022.12.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatology, 2023-05. Verfasst von Edmond Atallah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK; National Institut…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Psoriasis. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health.
Abstract (Originalsprache)
BACKGROUND & AIMS: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-reported risk factors for liver disease. We evaluated the risk of long-term MTX therapy on liver fibrosis in a longitudinal cohort study using two non-invasive markers. METHOD: Between 2014-2021, adult patients diagnosed with rheumatoid arthritis (RA) or psoriasis for ≥2 years were recruited prospectively from six UK sites. The MTX group included patients who received MTX for ≥6 months, whereas the unexposed group included those who never received MTX. All patients underwent full liver profiling, with transient elastography (TE) and enhanced liver fibrosis (ELF) marker measurements. RESULTS: A total of 999 patients (mean age 60.8 ± 12 years, 62.3% females) were included. Of 976 with valid TE values, 149 (15.3%) had liver stiffness ≥7.9 kPa. Of 892 with a valid ELF, 262 (29.4%) had ELF ≥9.8. Age and BMI were independently associated with elevated liver stiffness and ELF. Neither MTX cumulative dose nor duration was associated with elevated liver stiffness. Diabetes was the most significant risk factor associated with liver stiffness ≥7.9 kPa (adjusted odds ratio = 3.19; 95% CI 1.95-5.20; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK; National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, No…
- Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
- Academic Rheumatology, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK.
- Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
- University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
- Dept of Gastroenterology and Hepatology, Royal Surrey NHS Foundation Trust, Surrey, UK; Department of Clinical and Experimental Medicine, FHMS, University of Surrey, Surrey, UK; Institute of Liver Studies, Kings College…
Förderung
- Department of Health
Zitieren
APA
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., Jordan, K. M., Ala, A., Hutchinson, D., Aspinall, R. J., Murphy, R., & Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034
Vancouver
Atallah E, Grove JI, Crooks C, Burden-Teh E, Abhishek A, Moreea S, et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology. 2023;78(5):989-997. doi:10.1016/j.jhep.2022.12.034
BibTeX
@article{Atallah2023,
author = {Atallah, Edmond and Grove, Jane I and Crooks, Colin and Burden-Teh, Esther and Abhishek, Abhishek and Moreea, Sulleman and Jordan, Kelsey M and Ala, Aftab and Hutchinson, David and Aspinall, Richard J and Murphy, Ruth and Aithal, Guruprasad P},
title = {Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated},
journal = {Journal of Hepatology},
year = {2023},
volume = {78},
number = {5},
pages = {989--997},
doi = {10.1016/j.jhep.2022.12.034}
}
EUVIMED